Reuters logo
1 年前
BRIEF-Five Prime Therapeutics presents updated data from phase 1 trial
2016年6月6日 / 上午10点22分 / 1 年前

BRIEF-Five Prime Therapeutics presents updated data from phase 1 trial

June 6 (Reuters) - Five Prime Therapeutics Inc :

* Five Prime Therapeutics presents updated data from phase 1 trial of single-agent FPA144 at 2016 ASCO annual meeting

* Initial data show a 33% confirmed objective response rate, 77% disease control rate

* Initial data show 12-week progression free survival of 67% in 9 FGFR2B+ gastric cancer patients available for analysis

* Complete response seen in bladder cancer patient with moderate overexpression of FGFR2B protein

* No treatment-related serious adverse events (SAES); 17 reported SAES across 9 patients

* No treatment-related adverse events (AES) resulting in treatment discontinuation Source text: (1.usa.gov/1Pe8GtY) Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below